Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: a cross-sectional study of the National Health and Nutrition Examination Survey from 2007–2010

Respiratory Research

Janet B Croft⁴  Chaoyang Li²  Letitia Presley-Cantrell⁴  David M Mannino³  Anne G Wheaton⁴  Earl S Ford¹ 

[1] Centers for Disease Control and Prevention, 4770 Buford Highway, MS K67, Atlanta, GA, 30341, USA;Division of Behavioral Surveillance, Public Health Surveillance Program Office, Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA, USA;Department of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY, USA;Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA

关键词: Spirometry;    Risk factors;    Cardiovascular diseases;    Chronic obstructive pulmonary disease;   

Others  :  796575
DOI  :  10.1186/1465-9921-13-115

 received in 2012-10-05, accepted in 2012-12-10,  发布年份 2012

【 摘 要 】

Background

Reasons for the excess risk for cardiovascular disease among people with chronic obstructive pulmonary disease remain unclear. Our objective was to examine the cardiovascular risk profile for adults with obstructive and restrictive impairments of lung functioning in a representative sample of adults from the United States.

Methods

We used data from adults aged 20–79 years who participated in the National Health and Nutrition Examination Survey from 2007 to 2010 and had a pulmonary function test. The severity of obstructive impairment was defined by adapting the Global Initiative for Chronic Obstructive Lung Disease criteria.

Results

Among 7249 participants, 80.9% had a normal pulmonary function test, 5.7% had a restrictive impairment, 7.9% had mild obstructive impairment, and 5.5% had moderate or severe/very severe obstructive impairment. Participants with obstructive impairment had high rates of smoking and increased serum concentrations of cotinine. Compared to participants with normal pulmonary functioning, participants with at least moderate obstructive impairment had elevated concentrations of C-reactive protein but lower concentrations of total cholesterol and non-high-density lipoprotein cholesterol. Among participants aged 50–74 years, participants with at least a moderate obstructive impairment or a restrictive impairment had an elevated predicted 10-year risk for cardiovascular disease.

Conclusions

The high rates of smoking among adults with impaired pulmonary functioning, particularly those with obstructive impairment, point to a need for aggressive efforts to promote smoking cessation in these adults. In addition, adults with restrictive impairment may require increased attention to and fine-tuning of their cardiovascular risk profile.

【 授权许可】

   
2012 Ford et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung HC: Deaths: Preliminary Data for 2009. Natl Vital Stat Rep 2011, 59:1-51.
• [2]Ford ES, Mannino DM, Zhao G, Li C, Croft JB: Changes in mortality among US adults with COPD in two national cohorts recruited from 1971–1975 and 1988–1994. Chest 2012, 141:101-110.
• [3]Hansell AL, Walk JA, Soriano JB: What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003, 22:809-814.
• [4]Huiart L, Ernst P, Suissa S: Cardiovascular morbidity and mortality in COPD. Chest 2005, 128:2640-2646.
• [5]Mapel DW, Dedrick D, Davis K: Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991–1999. COPD 2005, 2:35-41.
• [6]Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005, 128:2068-2075.
• [7]Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D: Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16:63-70.
• [8]Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA: Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008, 63:599-605.
• [9]Mazza A, Zamboni S, Rubello D, Schiavon L, Zorzan S, Casiglia E: Chronic obstructive pulmonary disease and cardiovascular mortality in elderly subjects from general population. Blood Press 2010, 19:67-74.
• [10]Schneider C, Bothner U, Jick SS, Meier CR: Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010, 25:253-260.
• [11]Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM: Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996, 313:711-715.
• [12]Sin DD, Wu L, Man SF: The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005, 127:1952-1959.
• [13]Centers for Disease Control and Prevention: Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000–2004. MMWR Morb Mortal Wkly Rep 2008, 57:1226-1228.
• [14]Centers for Disease Control and Prevention: About the National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes/about_nhanes.htm webcite.
• [15]Centers for Disease Control and Prevention: Spirometry - 1st Test & 2nd Test Bronchodilator Studies. http://www.cdc.gov/nchs/nhanes/nhanes2009-2010/SPX_F.htm webcite.
• [16]Centers for Disease Control and Prevention: Spirometry - 1st Test & 2nd Test Bronchodilator Studies. http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/SPX_E.htm webcite.
• [17]Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
• [18]Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of COPD. Revised 2011. http://www.goldcopd.org/ webcite.
• [19]D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
• [20]Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS: Cardiovascular morbidity in COPD: A study of the general population. COPD 2010, 7:5-10.
• [21]Paek YJ, Jung KS, Hwang YI, Lee KS, Lee DR, Lee JU: Association between low pulmonary function and metabolic risk factors in Korean adults: the Korean National Health and Nutrition Survey. Metabolism 2010, 59:1300-1306.
• [22]Arcari A, Magnacca S, Bracone F, Costanzo S, Persichillo M, Di CA, De CA, Zito F, Schunemann HJ, Donati MB, et al.: Relation between pulmonary function and 10-year risk for cardiovascular disease among healthy men and women in Italy: the Moli-sani Project. Eur J Prev Cardiol 2012. in press. PMID:22609891.
• [23]The 2008 PHS Guideline Update Panel, Liaisons, and Staff: Treating Tobacco use and dependence: 2008 update. Clinical practice guideline. http://www.ahrq.gov/path/tobacco.htm webcite.
• [24]Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA: Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J 2009, 34:634-640.
• [25]Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP: Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010, 65:711-718.
• [26]Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
• [27]Mannino DM, Ford ES, Redd SC: Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003, 114:758-762.
• [28]Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006, 61:23-28.
• [29]Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
• [30]Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, Newby DE, Mills NL, MacNee W: Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011, 66:769-774.
• [31]Selcuk H, Maden O, Selcuk MT, Celenk MK, Geyik B, Tufekcioglu O: Documentation of impaired coronary blood flow in chronic obstructive pulmonary disease patients. Circ J 2010, 74:346-352.
• [32]Cella G, Sbarai A, Mazzaro G, Vanzo B, Romano S, Hoppensteadt T, Fareed J: Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost 2001, 7:205-208.
• [33]Moro L, Pedone C, Scarlata S, Malafarina V, Fimognari F, Antonelli-Incalzi R: Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology 2008, 59:357-364.
• [34]Maclay JD, McAllister DA, MacNee W: Cardiovascular risk in chronic obstructive pulmonary disease. Respirology 2007, 12:634-641.
• [35]Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, Newby DE, MacNee W: Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:513-520.
• [36]Sin DD, Man SF: Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008, 14:115-121.
• [37]Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD: Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010, 137:13-19.
• [38]Singh S, Loke YK, Furberg CD: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:1439-1450.
• [39]Oba Y, Zaza T, Thameem DM: Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 2008, 3:575-584.
• [40]Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza MV, Schiavi EA: Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009, 103:1421-1429.
• [41]Sindi A, McIvor A: The use of inhaled anticholinergics in chronic obstructive pulmonary disease: is there cause for concern? A review of evidence from clinical trials. Pol Arch Med Wewn 2009, 119:74-78.
• [42]Hilleman DE, Malesker MA, Morrow LE, Schuller D: A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis 2009, 4:253-263.
• [43]Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP: Cardiovascular safety of tiotropium in patients with COPD. Chest 2010, 137:20-30.
• [44]Salpeter SR, Ormiston TM, Salpeter EE: Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125:2309-2321.
• [45]Loke YK, Kwok CS, Singh S: Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J 2010, 35:1003-1021.
• [46]Owens RC Jr, Nolin TD: Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006, 43:1603-1611.
• [47]National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998, 6(Suppl 2):51S-209S.
• [48]U.S.Department of Health and Human Services: National Institutes of Health, National Heart LaBI. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2004.
• [49]Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001, 285:2486-2497.
• [50]Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, et al.: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases, American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106:388-391.
• [51]Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA: The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:776S-814S.
• [52]Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, et al.: Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:517-584.
• [53]van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, Simsek C, Stam H, Mertens FW, Bax JJ, et al.: Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008, 178:695-700.
• [54]Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM: Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47:2554-2560.
• [55]Gale NS, Duckers JM, Enright S, Cockcroft JR, Shale DJ, Bolton CE: Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med 2011, 11:20. BioMed Central Full Text
• [56]Reed RM, Iacono A, DeFilippis A, Eberlein M, Girgis RE, Jones S: Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J Heart Lung Transplant 2011, 30:674-678.
• [57]Tisi GM, Conrique A, Barrett-Connor E, Grundy SM: Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphysematous type). Metabolism 1981, 30:340-346.
• [58]Dobler CC, Wong KK, Marks GB: Associations between statins and COPD: a systematic review. BMC Pulm Med 2009, 9:32. BioMed Central Full Text
• [59]Young RP, Hopkins R, Eaton TE: Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009, 85:414-421.
• [60]Janda S, Park K, FitzGerald JM, Etminan M, Swiston J: Statins in COPD: a systematic review. Chest 2009, 136:734-743.
• [61]Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, Karas RH: Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003, 139:670-682.
• [62]Sin DD, Man SF: Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol 2007, 85:141-147.
• [63]Xu JF, Washko GR, Nakahira K, Hatabu H, Patel AS, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, et al.: Statins and pulmonary fibrosis: The potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012, 185:547-556.
• [64]Hsia CC: Cardiopulmonary limitations to exercise in restrictive lung disease. Med Sci Sports Exerc 1999, 31:S28-S32.
• [65]Mannino DM, Holguin F, Pavlin BI, Ferdinands JM: Risk factors for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis 2005, 9:613-621.
• [66]Leone N, Courbon D, Thomas F, Bean K, Jego B, Leynaert B, Guize L, Zureik M: Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009, 179:509-516.
• [67]Lin WY, Yao CA, Wang HC, Huang KC: Impaired lung function is associated with obesity and metabolic syndrome in adults. Obesity (Silver Spring) 2006, 14:1654-1661.
• [68]Fimognari FL, Pasqualetti P, Moro L, Franco A, Piccirillo G, Pastorelli R, Rossini PM, Incalzi RA: The association between metabolic syndrome and restrictive ventilatory dysfunction in older persons. J Gerontol A Biol Sci Med Sci 2007, 62:760-765.
• [69]Lim SY, Rhee EJ, Sung KC: Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. J Korean Med Sci 2010, 25:1480-1486.
• [70]Frieden TR, Berwick DM: The "Million Hearts" initiative-preventing heart attacks and strokes. N Engl J Med 2011, 365:e27.
• [71]Centers for Disease Control and Prevention: Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors-United States, 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1248-1251.